ClinicalTrials.gg
RecruitingNCT06528184Updated Feb 10, 2025

Evaluating the Impact of Different Methods of HPV DNA Testing for Cervical Cancer Screening in Primary Care Settings

An interventional study of Self-sampled HPV DNA testing and Clinician-sampled HPV DNA test in Uterine Cervical Neoplasms, sponsored by National Healthcare Group Polyclinics. Recruiting at 1 site in Singapore. Open to female participants aged 30 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-10.

Sponsored by National Healthcare Group Polyclinics · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
650
Allocation
Randomized
Ages
30 Years to 69 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies in Uterine Cervical Neoplasms with a site in Singapore — 2 open to participants now, 7 under way, 1 of them phase 3. Uterine Cervical Neoplasms · Singapore.

Planned enrollment
5th of 15
650 · median 289
Started
2024
with 2 others
No phase
3 of 18
2 open now
Registered
17th of 18
by date

Among the 18 studies in Uterine Cervical Neoplasms with a site in Singapore, this one is the 5th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2024, is one of 3 with no phase, and was the 17th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

2 of the 18 studies in Uterine Cervical Neoplasms with a site in Singapore are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 30 Years to 69 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Uterine Cervical Neoplasms with a site in Singapore, or all of them as a file.
02

Study summary

Primary objective of the study is to determine the extent that offering of self-sampling in addition to clinician-sampling Human Papillomavirus (HPV) DNA testing will increase detection of HPV DNA through an increase in uptake rates of cervical cancer screening as compared to offering clinician-sampling HPV DNA testing alone.

The hypothesis is that offering additional self-sampling will increase the detection of high-risk HPV DNA by at least 7.7%.

Read the detailed description

This study is a pragmatic, multi-center, 1:1 randomized controlled trial designed to evaluate the impact of self-sampling HPV DNA testing on clinical outcomes and cost-effectiveness in cervical cancer screening. The trial will compare 2 approaches to HPV DNA testing within public primary care settings.

Participants in the intervention arm will first be offered a clinician-sampling HPV DNA test. If they decline, they will be offered the option of self-sampling HPV DNA test. The control arm will follow the standard protocol of offering only the conventional clinician-sampling HPV DNA test, reflecting the current standard of care in cervical cancer screening.

This study seeks to provide robust evidence on whether self-sampling can improve clinical outcomes, be cost-effective and be feasibility implemented in routine public primary healthcare settings. The findings are expected to inform future guidelines and policies for cervical cancer screening programs.

03

Conditions studied

  • Uterine Cervical Neoplasms
04

Who can participate

Ages eligible
30 Years to 69 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 30-69 years old female Singapore citizens
  • Due for cervical cancer screening
  • Engaged in sexual intercourse before
  • Able to give
  • Able to read and communicate in English, Chinese or Malay

Exclusion criteria

Exclusion Criteria:

  • Virgo intacta
  • Pregnancy
  • History of cervical cancer, precancerous cervical lesions and total hysterectomy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
650 participants (estimated)

Study arms

  • Active comparator
    Usual care arm

    Participants will only be offered clinician-sampling for HPV DNA testing to determine if they are agreeable to undergo screening.

    Diagnostic Test: Clinician-sampled HPV DNA test

  • Experimental
    Intervention arm

    Participants will be offered clinician-sampling or self-sampling for HPV DNA testing to determine if they are agreeable to undergo screening using either modality.

    Diagnostic Test: Self-sampled HPV DNA testing · Diagnostic Test: Clinician-sampled HPV DNA test

Interventions

  • Diagnostic testSelf-sampled HPV DNA testing

    Participants will be offered HPV DNA testing done through self-sampling (using self-sampling HPV DNA kits to obtain a mid-vaginal swab)

  • Diagnostic testClinician-sampled HPV DNA test

    Participants will be offered HPV DNA testing through clinician sampling (clinician-sampling (speculum examination by a nurse to obtain a cervical swab)

06

What researchers measure

Primary outcomes

  1. Detection of high-risk Human Papillomavirus (HPV) DNA

    Difference in detection of high-risk HPV DNA between 2 arms

    Time frame: 3 months

Secondary outcomes

  1. Uptake of cervical cancer screening

    Difference in uptake of cervical cancer screening between 2 arms. Based on the number of cervical cancer screening tests that are processed and have available results.

    Time frame: 3 months

  2. Colposcopy referrals

    Difference in colposcopy referrals between 2 arms. Based on the number of colposcopy referrals made to the tertiary hospital for abnormal cervical cancer screening test results in either arm.

    Time frame: 2 years

  3. Detection of cervical intraepithelial neoplasia (CIN) 2, CIN 3 and cervical cancers

    Difference in detection of CIN 2, CIN 3 and cervical cancers between both arms.

    Time frame: 2 years

  4. Treatments for CIN 2, CIN 3 and cervical cancers

    Difference in treated CIN 2, CIN 3 and cervical cancers between both arms. Based on the number of participants with CIN 2, CIN 3 and cervical cancers that have undergone treatments by a gynecologist in either arm.

    Time frame: 2 years

  5. Cost-effectiveness of cervical cancer screening

    Difference in cost-effectiveness of offering cervical cancer screening between both arms. This includes the cost of screening and follow-up visits in primary care, the cost of further investigations in primary and tertiary care and the cost of treatment for CIN and cervical cancer in tertiary care.

    Time frame: 2 years

  6. Facilitators and barriers of uptake of cervical cancer screening

    Assessing the factors associated with uptake of cervical cancer screening. These factors include demographics of participants (age, ethnicity, education level, marital status, housing type, employment status), Body Mass Index, obstetrics-related factors (menopausal status, pregnancies, previous cervical cancer screening tests, use of tampons or menstrual cups, previous HPV vaccinations) as well as beliefs and attitudes towards cervical cancer screening. These variables will be collected from questionnaires.

    Time frame: 1 year

  7. Feasibility of self-sampling cervical cancer screening

    Assessing the preferences for next screening and the experience of the sampling procedure (ease of conducting, comfort, anxiety, embarrassment, unpleasantness and trusting of results) from questionnaires.

    Time frame: 1 year

  8. Risk factors for cervical cancer and CIN

    Assessing the factors associated with cervical cancer and CIN. These factors include demographics of participants, family history of cervical cancer, smoking status, use of contraceptives, immunosuppressive conditions and sexual history and obstetrics-related factors. These variables will be collected from questionnaires.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.

Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 28 months is below that.

Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2024
First posted
Jul 30, 2024
StartActual
Aug 5, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Feb 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06528184
Lead sponsor
National Healthcare Group Polyclinics
Collaborators
National Healthcare Group, Singapore, KK Women's and Children's Hospital
Responsible party
Ng Xin Rong (Family Physician, National Healthcare Group Polyclinics) — Principal investigator
First posted
Jul 30, 2024
Start date
Aug 5, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Feb 10, 2025

Study contacts

Ng Xin Rong, MBBS
Contact
xin_rong_ng@nhgp.com.sg
+65 63553000
Ng Xin Rong, MBBS
principal investigator · National Healthcare Group Polyclinics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion